New approach uses magnetic beads to treat pre-eclampsia
American Heart Association May 15, 2019
Preliminary laboratory tests show that functionalized magnetic beads successfully reduced blood levels of a harmful molecule that is elevated during pre-eclampsia, according to new research in the American Heart Association’s journal Hypertension.
Pre-eclampsia is a complication of pregnancy characterized by hypertension and kidney dysfunction that affects an estimated 6%–8% of women in the United States who give birth each year. Pre-eclampsia is responsible for severe complications in the mother (seizures, stroke, renal failure, liver dysfunction) and the infant (low birth weight, preterm delivery, stillbirth). The condition also increases a woman’s risk for cardiovascular disease later in life (stroke and high blood pressure). Currently, there’s no cure for pre-eclampsia, and only childbirth can alleviate symptoms.
Researchers focused on a molecule, called sFlt-1, which is released by the placenta into the woman’s bloodstream and rises to high levels during pre-eclampsia. High levels of sFlt-1 are responsible for blood vessel wall dysfunction, contributing to high blood pressure, and for trapping two other important molecules that enhance blood vessel wall function, called VEGF and PlGF.
Using blood from women with pre-eclampsia, researchers conducted laboratory tests to see if magnetic beads could essentially drag sFlt-1 out of circulation, therefore freeing up levels of VEGF and PlGF. They found that magnetic beads reduced sFlt-1 by 40% and freed up to two times more PlGF, reducing the sFlt-1/PlGF ratio by 63%.
“This was a proof of concept study and our approach aims to restore physiologic levels of angiogenic factors,” said lead study author Vassilis Tsatsaris, MD, PhD, a professor of obstetrics and gynecology at Cochin Hospital in Paris. “The reduction of sFlt-1 and the release of angiogenic factors is very significant and promising.”
Angiogenic factors are any of a group of substances present in the circulation—most of which are polypeptides (ie, angiogenin, fibroblast growth factor, transforming growth factors, and some lipids)—which help form blood vessels.
Based on the success of these early findings, Tsatsaris and his colleagues would like to expand their study and repeat these experiments to see if this approach can control pre-eclampsia and prolong pregnancy while reducing the risks of prematurity for the baby.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins